When was GlySure founded?

GlySure was founded in 2006 and raised its 1st funding round 6 years after it was founded.

Where is GlySure located?

GlySure is headquartered in Abingdon, United Kingdom. It is registered at 25 Moorgate, London, EC2R 6AY.

How many employees does GlySure have?

As of Jul 31, 2026, the latest employee count at GlySure is 8.

Is GlySure a funded company?

GlySure is a funded company, having raised a total of $24.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Jan 09, 2012.

When was the latest funding round of GlySure?

GlySure's latest funding was a $***** Series C round on Nov 28, 2012, with participation from 4 investors.

Where does GlySure rank among its competitors?

GlySure ranks 7th amongst 77 active competitors, of which 25 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Ethypharm, which secured $557K in Dec, 2023.

Who are the top competitors of GlySure?

GlySure's top competitors include ZOLL AEDs, InnAccel and vTitan. Among them, Ethypharm secured the most recent funding round in December, 2023.

GlySure - 2026 Company Profile, Team, Funding, Competitors & Financials

GlySure is a series C company based in Abingdon (United Kingdom), founded in 2006. It operates as a Continuous glucose monitoring using optical fluorescence sensor. GlySure has raised $24.5M in funding from Morningside. The company has 77 active competitors, including 25 funded and 12 that have exited. Its top competitors include companies like ZOLL AEDs, InnAccel and vTitan.

Company Details

GlySure has developed a continuous intravascular (I.V) glucose monitoring system using a proprietary optical fluorescence sensor for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company claims to have demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient’s stay in the ICU. Also, the company mentions that hospital TGC has shown in prospective outcomes trials to produce significant improvement in patient outcomes including 46% reduction in incidence of sepsis, 41% reduction in renal failure, and 34% reduction in mortality. As of December 2016, the Company is finalizing design of a clinical trial to support submission to the U.S. Food and Drug Administration (FDA).

Website: glysure.com
Social
Registered Address: 25 Moorgate, London, EC2R 6AY

Key Metrics

Founded Year

2006

Location

Abingdon, United Kingdom

Stage

Series C

Total Funding

$24.5M in 2 rounds

Latest Funding Round

Series C, Nov 28, 2012, $*****

Investors

Morningside & 6 more

Ranked

7^th among 77 active competitors

Employee Count

8 as on Jul 31, 2026

Similar Companies

ZOLL AEDs & 101 more

View GlySure's full profile

GlySure is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
GLYSURE LIMITED CIN: 4927435 , Germany, Active	Oct 08, 2003	-	6 (As on Mar 31, 2018)

GlySure has raised a total funding of $24.5M over 2 rounds. Its first funding round was on Jan 09, 2012. Its latest funding round was a Series C round on Nov 28, 2012 for $*****. 4 investors participated in its latest round. GlySure has 6 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of GlySure:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 28, 2012	4189554	Series C	2270640	3167092	8814067	5388017
Jan 09, 2012	8583800	Series C	4313859	1884830	Morningside	Amadeus Capital & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of GlySure's funding rounds and investors

GlySure's Board of Directors

GlySure's board has 6 active members. Roger Moody is part of team and Anne Margaret Glover, Barry Colin Crane, Patrick Robin David Paul, William Penn Moffitt and Frank Kenny are independent board members.

Here is the list of GlySure's board of directors:

Name	Type	Representing	Status	Duration
jjhflwd	Team	-	Current	2y 8m
Anne Margaret Glover	Independent board member	-	Current	19y 8m
hzj{erx	Independent board member	-	Current	2y 1m
maegix{	Independent board member	-	Current	3y 5m
ycmactd	Independent board member	-	Current	4y 9m
frlgqcs	Independent board member	-	Current	5y 6m
oozhkey	Independent board member	-	Past	3y 1m
zocbehn	Independent board member	-	Past	2y 7m
hrdrhsz	Independent board member	-	Past	4y 8m
spkwszt	Independent board member	-	Past	4y 9m
aqxkkkq	Independent board member	-	Past	2y 9m

GlySure's employee count trend

GlySure has 8 employees as of Jul 26. Here is GlySure's employee count trend over the years:

Uncover GlySure's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GlySure include ZOLL AEDs, InnAccel and vTitan. Here is the list of Top 10 competitors of GlySure, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ZOLL AEDs 1983, Chelmsford (United States), Acquired	Developer of medical devices and software solutions for emergency care	-	Nobel Investments, Military Health & 2 others	64/100
2nd	InnAccel 2012, Bengaluru (India), Seed	Developer of medical devices for critical care, obstetrics, and neonatology	$5.84M	Mount Judi Ventures, Acunova Life Sciences ... & 29 others	60/100
3rd	vTitan 2010, Chengalpattu (India), Seed	Manufacturer of a broad range of medical devices used in critical care units of hospitals	$10M	Zoho & 10 others	58/100
4th	Ethypharm 1977, Saint Cloud (France), Acquired	Developer of therapies for the treatment of pain and addiction	$248M	Astorg Partners, Biovail & 7 others	55/100
5th	Allied Medical 1982, Gurugram (India), Early Stage	Manufacturer of anesthesia and hospital equipment	$2.31M	Kabbir Kohil Family Trustes, Krrish Kohn Family Trust ... & 16 others	47/100
6th	Airway Medix 2010, Warsaw (Poland), Public	Developer of medical devices for ventilated patients in intensive care units	-	-	43/100
7th	GlySure 2006, Abingdon (United Kingdom), Series C	Continuous glucose monitoring using optical fluorescence sensor	$24.5M	Baxter, Delta Partners & 5 others	40/100
8th	Medivance 1998, Louisville (United States), Acquired	Non-invasive Temperature Management System	$59.2M	Camden Partners, Cross Atlantic Capital Partners ... & 5 others	40/100
9th	ART Medical 2009, Netanya (Israel), Series B	Developer of product for ICU based safe enteral nourishment	$27M	Israel Innovation Authority, Grand Challenges	39/100
10th	Velomedix 2007, Menlo Park (United States), Deadpooled	Provider of therapeutic hypothermia during ischemic or inflammatory attacks	$23.7M	Longitude Capital, Life Science Angels & 1 others	38/100